EPO and kidney cancer: Notably, kidney cancer patients frequently exhibit anemia, with up to 35% of cases demonstrating decreased levels of hemoglobin (HGB), hematocrit (HCT), MCV, and MCH due to the weak activity of erythropoietin (EPO) and abnormal iron metabolism (18, 19).